Search

Memorial Sloan Kettering plastic and reconstructive surgeon Michelle Coriddi describes breast reconstruction options for women undergoing mastectomy, including implants, flap surgery, TRAM flap, and DIEP flap, and more.

… Friday, October 13, 2023 Summary Women undergoing mastectomy as part of treatment for breast cancer not only have to cope with a cancer diagnosis and treatment but the decision of whether to have breast reconstructive surgery. Both options — implant surgery and flap surgery (in which the surgeon uses

Memorial Sloan Kettering Cancer Center (MSK) today announced it has received a new grant from the National Cancer institute (NCI), part of the National Institutes of Health, under the umbrella of the Cancer Moonshot, to create the MATCHES (Making Telehealth Delivery of Cancer Care at Home Effective and Safe) Telehealth Research Center at MSK, a first of its kind.

… Thursday, August 18, 2022 Memorial Sloan Kettering Cancer Center (MSK) today announced it has received a new grant from the National Cancer institute (NCI), part of the National Institutes of Health, under the umbrella of the Cancer Moonshot, to create the MATCHES (Making Telehealth Delivery of Cancer

A new project called the BRCA Exchange is sharing data about BRCA mutations and what they actually mean for cancer risk.

… Monday, February 11, 2019 Summary Clinical genetics experts from MSK and other institutions have launched the BRCA Exchange. This online database shares information about individual BRCA mutations and how they might increase cancer risk. Many people have heard that mutations in the genes BRCA1 and BRCA2

A protein detected in the urine of children with Wilms’ tumor led to the development of a test to improve diagnosis and treatment.

… Thursday, August 8, 2019 Summary Wilms’ tumor is the most common kidney cancer in children. Researchers have detected a protein called prohibitin in the urine of people with aggressive Wilms’ tumor. This discovery could help doctors identify people at risk for the cancer returning after treatment and

A groundbreaking international study has found that imlunestrant plus abemaciclib significantly improved progression-free survival (PFS) versus imlunestrant monotherapy in patients with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) breast cancer, regardless of prior CDK 4/6 inhibitors, ESR1 or PI3K pathway mutations.

… Wednesday, December 11, 2024 A groundbreaking international study has found that imlunestrant plus abemaciclib significantly improved progression-free survival (PFS) versus imlunestrant monotherapy in patients with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2-negative (ER

The largest, most comprehensive study of its kind from Memorial Sloan Kettering Cancer Center finds that the biology of colorectal cancer in people under 50 is very similar to the disease in older people and more aggressive treatment of younger patients may not be warranted.

… Wednesday, August 18, 2021 Could colorectal cancer in people under 50 years old be biologically different and more aggressive than colorectal cancer in older people? That’s what some researchers have proposed as people in their 20s, 30s, and 40s face a disturbing rise in colorectal cancer — people who

El estudio más grande y más completo de su tipo, realizado por el Memorial Sloan Kettering Cancer Center, concluye que la biología del cáncer colorrectal en personas menores de 50 años es muy similar a la de los pacientes de mayor edad, y que podría no estar justificado aplicar tratamientos más agresivos en los pacientes más jóvenes.

… Wednesday, August 18, 2021 ¿Podría el cáncer colorrectal en las personas menores de 50 años ser biológicamente diferente y más agresivo que el cáncer colorrectal en las personas mayores? Eso es lo que algunos investigadores han propuesto, ya que las personas de 20, 30 y 40 años se enfrentan a un aumento

Learn how a new imaging approach lights up nerves so they can be avoided during prostate cancer surgery.

… Wednesday, July 9, 2025 Men having  prostate cancer  surgery often fear  side effects  that can result from the procedure. Removing the tumor risks damage to surrounding nerves, resulting in erectile dysfunction and incontinence. Now a new way to light up nerves during the operation may help surgeons

Memorial Sloan Kettering Cancer Center (MSK) researchers published new results that found that individuals with low-risk or intermediate-risk myeloma precursor disease known as monoclonal gammopathy of undetermined significance (MGUS) can convert to high-risk MGUS and progress to multiple myeloma within a five-year window. This research clinically supports recommendations for annual blood tests for all individuals diagnosed with MGUS along with re-assessments of a patient’s clinical-risk status. Their research was published today online in JAMA Oncology.

… Thursday, July 18, 2019 Memorial Sloan Kettering Cancer Center (MSK) researchers published new results that found that individuals with low-risk or intermediate-risk myeloma precursor disease known as monoclonal gammopathy of undetermined significance (MGUS ) can convert to high-risk MGUS and progress

AACR Project GENIE steering committee head and Chair of MSK’s Human Oncology and Pathogenesis Program, Dr. Charles Sawyers, discusses how the first batch of genomic sequencing data fulfills an unmet need in oncology.

… Wednesday, February 15, 2017 In early 2017 a global collaboration of eight cancer centers led by Memorial Sloan Kettering and coordinated by the American Association for Cancer Research (AACR), released its first batch of data: genomic sequencing information on tumors from over 19,000 cancer patients